Morton Brown Family Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Morton Brown Family Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47K	Hold	400	–	–	﹤0.01%	280
2026 Q1	$1.23K	Hold	400	–	–	﹤0.01%	263
2025 Q4	$1.64K	Hold	400	–	–	﹤0.01%	262
2025 Q3	$1.95K	Hold	400	–	–	﹤0.01%	243
2025 Q2	$2.02K	Hold	400	–	–	﹤0.01%	281
2025 Q1	$2.12K	Hold	400	–	–	﹤0.01%	279
2024 Q4	$2.7K	Hold	400	–	–	﹤0.01%	221
2024 Q3	$2.64K	Hold	400	–	–	﹤0.01%	219
2024 Q2	$3.15K	Buy	+400	New	+$3.49K	﹤0.01%	183

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

TMC

Themes Management Co Greenwich, Connecticut $151M AUM

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Morton Brown Family Wealth's RXRX Position: Q2 2026 in Review

Morton Brown Family Wealth held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 400 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #280.

Morton Brown Family Wealth first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.15K in Q2 2024. 58 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Morton Brown Family Wealth held 400 shares of Recursion Pharmaceuticals worth $1.47K as of Q2 2026.
Morton Brown Family Wealth left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Morton Brown Family Wealth's portfolio in Q2 2026, its #280 holding.
Morton Brown Family Wealth first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Morton Brown Family Wealth's Recursion Pharmaceuticals position peaked at $3.15K in Q2 2024.
58 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Morton Brown Family Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.